Novartis Bioventures Ltd

CIK 1297709 · View on SEC EDGAR ↗

Insider

First SEC filing: March 19, 2014 · Latest: March 19, 2014

On this page

Insider at

Insider transactions

0 buys (P) 0 sells (S) Net: $0 + 4 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

4 other filings hidden
Date Ticker Code Shares Price Value Owned after Δ own A/D vs now
March 25, 2014 AKBA P 182,590 $17.00 $3,104,030 182,590 Direct — Acquired -94.6% (price as of 2026-08-21)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II)

Options, RSUs and convertible securities reported on Form 4 Table II.

Date Ticker Security Underlying Exercise price Expiration Shares A/D
March 25, 2014 AKBA Series A Convertible Preferred Stock Common Stock (1,285,156) — — 257,031 Disposed
March 25, 2014 AKBA Series B Convertible Preferred Stock Common Stock (608,704) — — 347,831 Disposed
March 25, 2014 AKBA Series C Convertible Preferred Stock Common Stock (1,329,314) — — 708,647 Disposed

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Initial ownership (Form 3) 3 holdings

Securities held when first becoming an insider, per SEC Form 3.

Date Ticker Security Shares Ownership
March 19, 2014 AKBA Series A Convertible Preferred Stock→ Common Stock (1,285,156) 1,285,156 Direct
March 19, 2014 AKBA Series B Convertible Preferred Stock→ Common Stock (608,704) 608,704 Direct
March 19, 2014 AKBA Series C Convertible Preferred Stock→ Common Stock (1,329,314) 1,329,314 Direct